Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | DHFR | P00374 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levofacetoperane SCHEMBL15003778 | 1.00 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Levofacetoperane SCHEMBL1651100 | 1.00 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL16437809 | 0.86 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL27995473 | 0.82 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL12495085 | 0.82 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL27884792 | 0.81 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL15705102 | 0.81 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL15705103 | 0.81 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL28152622 | 0.81 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Acetic Acid SCHEMBL5466781 | 0.80 | SLC6A3 (0.71) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2520 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| EP-4178615-A1 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2023-05-17 | — | — | EP | claimed |
| US-20220054471-A1 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | NLS PHARMACEUTICS AG (CH) | 2022-02-24 | — | — | US | claimed |
| US-11225490-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-18 | — | — | US | claimed |
| WO-2022011358-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2022-01-13 | — | — | WO | claimed |
| WO-2003063781-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | claimed |
| JP-2001524960-A | — | — | 2001-12-04 | — | — | JP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |